real-time news and commentary for investors
Thursday, Oct 17
Ariad rises after JPMorgan defends shares
- Beleaguered Ariad Pharmaceuticals (ARIA +10.4%) is enjoying a strong session thus far.
- Market chatter (here, here, and here) indicates that the move is likely attributable to a JPMorgan note in which analysts say physicians may be less concerned about Iclusig's safety profile than investors.
- JPM price target reportedly is $12.
- More on the Iclusig issue here